

Revenue beat; earnings quality under lens

Information Technology ▶ Result Update ▶ July 25, 2025

CMP (Rs): 1,676 | TP (Rs): 1,850

Coforge reported a mixed operating performance in Q1 with strong revenue growth, while margin missed our estimate. Revenue grew 9.6% QoQ to USD442mn (8% in CC; organic 5.9% in CC), better than our expectations. Revenue growth was led by TTH (31.2% QoQ; contributed over 60% of incremental revenue in Q1, owing to Sabre deal ramp-up), Others (12.8%), and Government outside India (6.8%). Adj EBITM was flat QoQ at 13.2%; however, reported EBITM declined by 50bps to 11.3%, lower than expected. In Q1, Coforge signed 5 large deals totaling USD507mn, lifting the next 12M executable orderbook to USD1.55bn, up ~47% YoY. The management remains confident about the revenue growth momentum continuing in FY26, on deal wins and the pipeline. It guided for adj EBITM of 14% in FY26. Quality of earnings is reflected in the gap between reported EBITM and adj EBITM; higher capex (USD65mn in Q1; USD85mn in the last two quarters) on AI-powered data centers and poor cash conversion remain areas of concern. We revised adj EPS estimates by -5.8% to 1.1% over FY26-28E, factoring in Q1 performance and the outlook. Considering the strong execution track record, expectations of a similar improvement in the reported EBITM trajectory as implied for the adjusted EBITM guidance, and better FCF conversion likely with moderation in capex intensity, we retain ADD with TP of Rs1,850, at 36x Jun-27E EPS.

Results summary

Revenue grew 9.6% QoQ (8% in CC, organic 5.9% in CC) to USD442.4mn, better than our expectations of 7% in CC. Revenue growth was driven by TTH (31.2% QoQ), Others—primarily Healthcare, Retail, Hi-Tech, Manufacturing (12.8%), Government outside India (6.8%), and Insurance (1%), while BFS declined 1.1% QoQ. Adj EBITM was flat QoQ at 13.2%; however, reported EBITM declined by 50bps to 11.3%. Reported net profit grew ~21.4% QoQ to Rs3.2bn due to a one-off gain from disposal of stake in AdvantageGo to the tune of Rs702mn. Adj net profit (adj for one-off transaction-related expenses, legal costs, and one-time bonus of Rs749mn) grew 36.5% QoQ to Rs3.9bn, above our estimate. Deal intake TCV stood at USD507mn vs USD2,126mn in Q4. Headcount grew ~2.1% QoQ to 34,187. LTM attrition increased to 11.3%, from 10.9% in Q4. The company declared interim dividend of Rs4/sh. **What we liked:** Revenue growth momentum, strong deal intake. **What we did not like:** Margin miss, weak FCF.

Earnings call KTAs

1) The company remains confident about sustaining the growth momentum on execution intensity, hyper-specialization in a few select industries, deep engineering capabilities, and assets. It expects H2 to be stronger than H1. 2) The mgmt remains confident about delivering 14% adjusted EBITM in FY26 on likely lower ESOP costs, continued revenue growth momentum, SG&A leverage, and the offshore shift...(contd)...

Target Price – 12M	Jun-26
Change in TP (%)	(5.6)
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	10.4

Stock Data	COFORGE IN
52-week High (Rs)	2,005
52-week Low (Rs)	1,120
Shares outstanding (mn)	334.5
Market-cap (Rs bn)	561
Market-cap (USD mn)	6,488
Net-debt, FY26E (Rs mn)	(784.9)
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	3,973.1
ADTV-3M (USD mn)	46.0
Free float (%)	99.5
Nifty-50	25,062.1
INR/USD	86.4


Shareholding, Mar-25

Promoters (%)	0.0
FPIs/MFs (%)	40.2/49.9

Price Performance

(%)	1M	3M	12M
Absolute	(10.0)	15.6	32.3
Rel. to Nifty	(9.3)	10.9	28.8

1-Year share price trend (Rs)



Coforge: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	91,790	120,507	160,424	188,458	218,000
EBITDA	14,277	16,937	27,891	32,690	37,599
Adj. PAT	8,080	8,121	14,109	16,274	19,661
Adj. EPS (Rs)	26.1	24.3	42.2	48.7	58.8
EBITDA margin (%)	15.6	14.1	17.4	17.3	17.2
EBITDA growth (%)	11.5	18.6	64.7	17.2	15.0
Adj. EPS growth (%)	9.2	(7.1)	73.7	15.3	20.8
RoE (%)	24.1	16.2	20.7	21.0	22.1
RoIC (%)	29.8	17.9	21.1	23.1	26.5
P/E (x)	64.1	69.0	40.2	32.4	27.0
EV/EBITDA (x)	36.4	30.6	18.6	15.9	13.8
P/B (x)	14.3	8.8	7.7	6.7	5.7
FCFF yield (%)	1.2	1.3	0.8	3.3	4.1

Source: Company, Emkay Research

Dipeshkumar Mehta

dipeshkumar.mehta@emkayglobal.com
+91-22-66121253

Jimit Gandhi

jimit.gandhi@emkayglobal.com
+91-22-66121255

Shivang Bagla

shivang.bagla@emkayglobal.com
+91-22-66242491

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

...(contd)...3) It invested USD85mn in an AI-powered data center over the last two quarters, with USD62mn received as advance from clients and recorded as deferred revenue, while USD23mn was funded through a term loan. The assets have a useful life of 5 years, resulting in an increase in D&A. Coforge expects capex intensity to normalize at 2-3% of revenue ahead. 4) Q1 was strong in terms of order intake and large deal closures. The company added 6 clients in Q1. 5) It expects OCF/EBITDA to be at 65-70%. 6) It signed 5 large deals in Q1 and targets 20 large deals in FY26. The mgmt indicated that the velocity and the median size of large deals signed has been increasing over the years. The 5 large deals include – a) a deal with one of the top three clients of Cigniti – an AI-infused app modernization deal (USD30mn TCV) with a US-based client, b) a deal with a North American client – digital transformation to scale-up various customer and enterprise processes on Pega Cloud, c) a deal with a North America-based client – transformation of the workplace platform, and integration with AI-enabled Microsoft services, d) a deal to build GCC for a Middle-East-based client to help transform its exchange operations, and e) a deal to transform tech infrastructure to enable scaling up of tax services for a client in Asia. 7) The Sabre deal is expected to continue to ramp up in Q2, with resource-loading and total headcount anticipated to stabilize from Q3. 8) The company has successfully leveraged Cigniti's acquisition for cross-selling, securing large deals with two of Cigniti's top three clients, and is actively pursuing opportunities with the third. 9) BFSI is seeing healthy demand across commercial banking, lending, wealth management, and risk/compliance, driven by margin pressures and regulatory changes. 10) The company provided a one-time broad-based bonus (USD5.5mn) to employees. 11) The unwinding of the discount is an accounting entry where the amount rises over time as interest accrues, then drops at maturity, with the corresponding value recorded as receivable. 12) Coforge plans to hike wages in Q3 and expects its impact to be partly negated by an anticipated reduction in ESOP costs. 13) It added 1,164 employees in Q1 to support large deal ramp-ups. 14) The merger process with respect to Cigniti is underway, with exchange approvals received and NCLT filing in progress; the effective date of merger was 1-Apr-25.

Update on AI/Gen AI

1) The company sees strong potential in AI integration, with AI budgets expanding at double-digit rates and becoming the primary engine for innovation and competitive advantage. 2) It launched the Coforge AgentSphere Platform with over 100 foundational agents that can address industry pain points across travel, financial services, and healthcare clients. 3) It now has over 20 core AI assets that accelerate the execution of services, such as reverse engineering of legacy code, intelligent test automation, and resilient cloud and infrastructure operations. 4) Quasar AI marketplace has more than 100 case examples of industry-specific solutions.

Exhibit 1: Quarterly snapshot

(Rs mn)	Q1FY26	Q4FY25	QoQ (%)	Q1FY25	YoY (%)
Revenue (USD mn)	442.4	403.5	9.6	286.6	54.4
Revenue	36,886	34,099	8.2	24,008	53.6
Operating expenses	30,903	28,351		19,921	
EBITDA	5,983	5,748	4.1	4,087	46.4
Margins (%)	16.2	16.9	(60)	17.0	(80)
Depreciation	1,584	1,254		815	
EBIT	4,399	4,494	-2.1	3,272	34.4
Margins (%)	11.9	13.2	(130)	13.6	(170)
Other income	-747	-561		-1,225	
Pre-tax profit	3,652	3,933	-7.2	2,047	78.4
Tax provided	792	874		654	
Minority Interest	-312	447		61	
Profit after tax	3,172	2,612		1,332	
Emkay Net profit	3,463	2,873	20.5	2,285	51.6
EPS (Rs)	10.4	8.6	20.5	6.9	51.1

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates

(Rs mn)	Actual	Estimate		Variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Net revenues (USD mn)	442	439	434	0.8%	2.0%	Revenue growth was better than estimate.
Sales	36,886	37,580	37,189	-1.8%	-0.8%	
EBIT	4,399	5,137	5,002	-14.4%	-12.1%	EBITM was below estimate.
EBIT margin	11.9%	13.7%	13.4%	-170 bps	-150 bps	
Adj. PAT	3,463	3,243	3,336	6.8%	3.8%	Reported PAT missed expectations due to exceptional items (expenses related to Cigniti merger, acquisitions, AdvantageGo divestment, and a one-time bonus) and lower other income.


Source: Company, Bloomberg, Emkay Research

Exhibit 3: Changes in estimates

(Rs mn)	FY26E			FY27E			FY28E		
	Old	New	Change	Old	New	Change	Old	New	Change
Revenue (USD mn)	1,858	1,871	0.7%	2,138	2,154	0.7%	2,458	2,477	0.8%
YoY growth	28.6%	29.4%		15.1%	15.1%		15.0%	15.0%	
Revenue	160,306	160,424	0.1%	187,083	188,458	0.7%	216,329	218,000	0.8%
EBIT	21,971	21,477	-2.2%	26,158	25,496	-2.5%	30,245	29,699	-1.8%
EBIT margin (%)	13.7	13.4		14.0	13.5		14.0	13.6	
Net Profit	13,958	14,109	1.1%	17,277	16,274	-5.8%	20,725	19,661	-5.1%
EPS (Rs)	41.7	42.2	1.1%	51.7	48.7	-5.8%	62.0	58.8	-5.1%

Source: Company, Emkay Research

Exhibit 4: Coforge – One-year forward PER



Source: Company, Emkay Research

Coforge: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	91,790	120,507	160,424	188,458	218,000
Revenue growth (%)	14.5	31.3	33.1	17.5	15.7
EBITDA	14,277	16,937	27,891	32,690	37,599
EBITDA growth (%)	11.5	18.6	64.7	17.2	15.0
Depreciation & Amortization	3,186	4,276	6,414	7,194	7,900
EBIT	11,091	12,661	21,477	25,496	29,699
EBIT growth (%)	8.5	14.2	69.6	18.7	16.5
Other operating income	-	-	-	-	-
Other income	614	1,666	70	(76)	223
Financial expense	1,256	1,366	1,809	1,490	1,182
PBT	10,449	12,961	19,738	23,930	28,740
Extraordinary items	0	0	(291)	0	0
Taxes	2,093	3,326	4,741	5,982	7,185
Minority interest	(276)	(1,514)	(888)	(1,673)	(1,894)
Income from JV/Associates	-	-	-	-	-
Reported PAT	8,080	8,121	13,818	16,274	19,661
PAT growth (%)	19.0	0.5	70.2	17.8	20.8
Adjusted PAT	8,080	8,121	14,109	16,274	19,661
Diluted EPS (Rs)	26.1	24.3	42.2	48.7	58.8
Diluted EPS growth (%)	9.2	(7.1)	73.7	15.3	20.8
DPS (Rs)	15.5	15.2	16.0	17.6	21.6
Dividend payout (%)	59.2	62.8	38.7	36.2	36.7
EBITDA margin (%)	15.6	14.1	17.4	17.3	17.2
EBIT margin (%)	12.1	10.5	13.4	13.5	13.6
Effective tax rate (%)	20.0	25.7	24.0	25.0	25.0
NOPLAT (pre-IndAS)	8,869	9,412	16,318	19,122	22,274
Shares outstanding (mn)	309	334	334	334	334

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	618	669	669	669	669
Reserves & Surplus	35,648	63,123	71,590	81,979	94,416
Net worth	36,266	63,792	72,259	82,648	95,085
Minority interests	1,003	19,498	20,386	22,059	23,953
Non-current liab. & prov.	(5,117)	(5,470)	(5,470)	(5,470)	(5,470)
Total debt	4,366	7,005	5,000	2,000	0
Total liabilities & equity	39,412	88,524	96,570	106,400	119,541
Net tangible fixed assets	4,760	7,682	12,098	11,115	10,448
Net intangible assets	4,395	11,296	9,098	7,020	4,727
Net ROU assets	2,637	3,554	4,232	4,670	4,960
Capital WIP	232	4,131	4,131	4,131	4,131
Goodwill	11,738	38,430	40,930	40,930	40,930
Investments [JV/Associates]	0	0	0	0	0
Cash & equivalents	3,352	8,832	5,785	14,142	26,102
Current assets (ex-cash)	28,380	45,512	54,754	64,614	74,732
Current Liab. & Prov.	16,082	30,913	34,278	40,221	46,489
NWC (ex-cash)	12,298	14,599	20,296	24,393	28,243
Total assets	39,412	88,524	96,570	106,400	119,541
Net debt	1,014	(1,827)	(785)	(12,142)	(26,102)
Capital employed	39,412	88,524	96,570	106,400	119,541
Invested capital	33,191	72,007	82,423	83,458	84,348
BVPS (Rs)	117.3	190.8	216.1	247.1	284.3
Net Debt/Equity (x)	-	-	-	(0.1)	(0.3)
Net Debt/EBITDA (x)	0.1	(0.1)	-	(0.4)	(0.7)
Interest coverage (x)	9.3	10.5	11.9	17.1	25.3
RoCE (%)	30.5	21.7	22.9	24.9	26.5

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	10,449	12,536	19,447	23,930	28,740
Others (non-cash items)	5,046	6,483	6,414	7,194	7,900
Taxes paid	(3,661)	(3,959)	(4,741)	(5,982)	(7,185)
Change in NWC	(2,800)	(2,689)	(5,001)	(3,328)	(3,041)
Operating cash flow	9,034	12,371	16,119	21,813	26,414
Capital expenditure	(2,598)	(5,572)	(11,810)	(4,570)	(5,230)
Acquisition of business	0	(20,810)	0	0	0
Interest & dividend income	120	714	0	0	0
Investing cash flow	(2,478)	(24,483)	(11,810)	(4,570)	(5,230)
Equity raised/(repaid)	7	22,015	-	0	0
Debt raised/(repaid)	(2,556)	2,139	(2,005)	(3,000)	(2,000)
Payment of lease liabilities	0	(866)	0	0	0
Interest paid	-	-	-	-	-
Dividend paid (incl tax)	(4,781)	(5,097)	(5,351)	(5,886)	(7,224)
Others	(1,540)	(1,438)	0	0	0
Financing cash flow	(8,870)	16,753	(7,356)	(8,886)	(9,224)
Net chg in Cash	(2,314)	4,641	(3,047)	8,357	11,960
OCF	9,034	12,371	16,119	21,813	26,414
Adj. OCF (w/o NWC chg.)	11,834	15,060	21,120	25,141	29,455
FCFF	6,436	6,799	4,309	17,243	21,184
FCFE	5,300	6,147	2,500	15,752	20,002
OCF/EBITDA (%)	63.3	73.0	57.8	66.7	70.3
FCFE/PAT (%)	65.6	75.7	18.1	96.8	101.7
FCFF/NOPLAT (%)	72.6	72.2	26.4	90.2	95.1

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	64.1	69.0	40.2	32.4	27.0
EV/CE(x)	12.5	5.7	5.3	4.9	4.4
P/B (x)	14.3	8.8	7.7	6.7	5.7
EV/Sales (x)	5.7	4.3	3.2	2.8	2.4
EV/EBITDA (x)	36.4	30.6	18.6	15.9	13.8
EV/EBIT(x)	46.8	41.0	24.2	20.4	17.5
EV/IC (x)	15.6	7.2	6.3	6.2	6.2
FCFF yield (%)	1.2	1.3	0.8	3.3	4.1
FCFE yield (%)	0.9	1.1	1.7	2.9	3.8
Dividend yield (%)	0.9	0.9	0.9	1.0	1.3
DuPont-RoE split					
Net profit margin (%)	8.8	6.7	8.8	8.6	9.0
Total asset turnover (x)	2.7	2.0	1.8	1.9	2.0
Assets/Equity (x)	1.0	1.2	1.3	1.3	1.2
RoE (%)	24.1	16.2	20.7	21.0	22.1
DuPont-RoIC					
NOPLAT margin (%)	9.7	7.8	10.2	10.1	10.2
IC turnover (x)	3.1	2.3	2.1	2.3	2.6
RoIC (%)	29.8	17.9	21.1	23.1	26.5
Operating metrics					
Core NWC days	48.9	44.2	46.2	47.2	47.3
Total NWC days	48.9	44.2	46.2	47.2	47.3
Fixed asset turnover	3.0	2.3	2.1	2.2	2.4
Opex-to-revenue (%)	84.3	85.9	82.6	82.7	82.8


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jul-25	1,923	1,960	Add	Dipeshkumar Mehta
06-May-25	1,485	1,640	Add	Dipeshkumar Mehta
31-Mar-25	1,622	1,640	Reduce	Dipeshkumar Mehta
24-Jan-25	1,847	1,720	Reduce	Dipeshkumar Mehta
01-Jan-25	1,926	1,720	Reduce	Dipeshkumar Mehta
29-Dec-24	1,890	1,350	Reduce	Dipeshkumar Mehta
23-Oct-24	1,512	1,350	Reduce	Dipeshkumar Mehta
01-Oct-24	1,425	1,280	Reduce	Dipeshkumar Mehta
23-Jul-24	1,236	1,240	Reduce	Dipeshkumar Mehta
01-Jul-24	1,104	1,100	Reduce	Dipeshkumar Mehta
09-Jun-24	1,086	1,040	Reduce	Dipeshkumar Mehta
03-Jun-24	1,003	1,040	Reduce	Dipeshkumar Mehta
27-May-24	1,053	1,040	Reduce	Dipeshkumar Mehta
03-May-24	897	1,040	Reduce	Dipeshkumar Mehta
31-Mar-24	1,100	1,210	Reduce	Dipeshkumar Mehta
01-Mar-24	1,301	1,260	Reduce	Dipeshkumar Mehta
23-Jan-24	1,240	1,260	Reduce	Dipeshkumar Mehta
31-Dec-23	1,255	1,260	Reduce	Dipeshkumar Mehta
30-Nov-23	1,152	1,010	Reduce	Dipeshkumar Mehta
20-Oct-23	1,000	1,010	Hold	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 25, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 25, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 25, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.